When OCA becomes the right option

A scan finding of a talar dome lesion does not automatically mean an allograft is needed — for most patients, the journey to that decision passes through several earlier steps, and many people never reach it.

Osteochondral lesions of the talus (OLT) are most commonly post-traumatic, arising after ankle sprains or fractures, and tend to affect younger, active individuals rather than those with widespread joint degeneration. That matters, because the typical OCA candidate is precisely this group: a patient with a focal, contained defect in an otherwise healthy ankle.

The first step is always conservative management. Activity modification, bracing, anti-inflammatory medication, and protected weight-bearing successfully resolve around 50% of acute, non-displaced lesions — so any surgical conversation waits until that avenue has been genuinely exhausted.

When surgery is indicated, bone marrow stimulation (microfracture) is first-line for smaller defects. The evidence identifying its limits is unusually clear. Chuckpaiwong et al. (2008), studying 105 ankle lesions, recorded zero treatment failures for lesions below a 15 mm average diameter — but only a 3% success rate for those at or above that threshold. A complementary MRI-based analysis by Choi et al. (2009), covering 168 lesions, placed the cutoff at 150 mm²: larger lesions predicted poor outcomes after microfracture.

These two thresholds define the primary gateway into OCA consideration. A second gateway exists independently of size: any patient whose lesion has already failed bone marrow stimulation becomes a candidate, regardless of how modest the defect appeared on initial imaging.

What the procedure involves

Sourcing a well-matched graft is the starting point. OCA uses a fresh donor plug — cartilage and underlying bone taken from a cadaveric donor — sized and shaped to correspond precisely with the patient's lesion. The word fresh matters: unlike cryopreserved tissue, a fresh allograft retains living chondrocytes, which are considered important for durable integration. Graft preparation and timing involve coordination with specialist tissue banks, and the window between procurement and implantation is something surgical teams plan carefully around.

Surgical access is the most technically demanding aspect of the operation. The talar dome sits deep within the ankle joint, and most lesions cannot be reached without creating a deliberate opening. Medially located lesions typically require a medial malleolar osteotomy — a chevron-shaped cut through the inner ankle bone — to expose the defect. Lateral lesions require a tibial trapezoidal osteotomy. Both approaches involve dividing and then re-fixing bone, which means two structures must heal after surgery: the cartilage repair itself and the osteotomy site. That dual healing commitment is a material factor in rehabilitation timelines and is worth discussing in detail before the procedure.

Preoperative planning combines CT and MRI used together. CT defines bony morphology, maps lesion dimensions across planes, and — with images taken in maximal plantar flexion — helps confirm whether arthroscopic access is achievable or an osteotomy is unavoidable. MRI contributes cartilage-specific detail: it detects non-displaced lesions invisible on plain radiograph and identifies subchondral oedema relevant to staging. Together, these images form the basis for the consultant's graft specification and surgical plan.

Survivorship and functional outcomes

Graft survivorship figures for OCA are encouraging — but before quoting them, it is worth being clear about where most of the data comes from. The bulk of long-term outcome evidence is drawn from knee series, where case volumes are large enough to support multi-decade follow-up studies. Talar dome–specific OCA data exists, but the ankle cohorts are considerably smaller and most come from single-institution retrospective series; no large randomised controlled trial specific to talar dome OCA has been conducted.

With that context stated, the knee-derived survivorship benchmarks are: 82.6% graft survival at five years and 69.6% at ten years in one cohort, and 95% survival at a mean of 12.9 years in a separate series where 68% of 65 grafts remained in situ and functioning. At six-year follow-up, 75.2% of patients had returned to sport or recreational activity, and 71% achieved very good or excellent joint function.

When a primary graft does fail, revision OCA is a meaningful option rather than an automatic step towards joint replacement. A patellofemoral salvage cohort reported mean survival of 87.9% at five years and 77.2% at ten years following revision transplantation, with clinically meaningful improvement in outcome scores across all included studies.

The caveat about ankle biology is genuine rather than merely cautionary. Ankle cartilage carries a lower water content and a higher concentration of glycosaminoglycans than knee cartilage, giving it distinct biomechanical properties and healing behaviour. Knee-derived survival curves therefore offer a reasonable working reference for what OCA can achieve, but ankle-specific long-term data — as it matures — may tell a somewhat different story.

How OCA compares to other cartilage repair options

Four techniques occupy the talar dome repair pathway, separated primarily by lesion size and subchondral bone status — and understanding where each one stops being the right answer makes the allograft decision clearer.

Microfracture

Historically the default first arthroscopic step, microfracture produces fibrocartilage rather than hyaline tissue. That distinction matters over time: the repair tends to deteriorate at two to three years, and the subchondral drilling can compromise the bone plate in ways that restrict future options. Within the size thresholds discussed earlier, it retains a defined role; for larger or previously treated lesions, it is not a modern first choice.

OATS / mosaicplasty

When autologous tissue is available and sufficient in volume, autologous osteochondral transfer performs well. Zengerink et al.'s 2009 systematic review of 243 patients reported 87% success for autologous osteochondral transplantation in ankle lesions, with some individual series reaching 100%. The ceiling is coverage: larger talar defects exceed what autograft plugs can fill, and harvesting carries its own donor-site morbidity. That size limit is the primary reason allograft emerges as a distinct pathway.

MACI

For borderline defects where autograft volume is insufficient but the subchondral bone is largely intact, MACI is a credible two-stage alternative. The SUMMIT trial demonstrated significantly improved KOOS pain and function scores at two and five years for defects of 3 cm² or more with MACI versus microfracture — making it relevant wherever OCA and MACI are both being weighed.

OCA

Allograft addresses what the others cannot: defects too large for autologous coverage, full-thickness bone loss, or a subchondral plate already compromised by prior marrow stimulation. When both lesion size and bone status point toward OCA, the case for allograft is largely made — and the relevant question shifts from which technique to choose toward surgical planning and graft matching.

Recovery: what the timeline realistically looks like

Recovery from talar dome OCA is measured in months, not weeks — and where a malleolar osteotomy was required for surgical access, that timeline extends further still, because bone healing at the osteotomy site runs in parallel with cartilage integration rather than completing first.

The early phase typically involves protected weight-bearing with crutches for six to eight weeks, with the exact duration varying by surgeon preference and the extent of bony work carried out. Progressive loading follows, guided jointly by the operating surgeon and a physiotherapist, with ankle range-of-motion work introduced as osteotomy stability is confirmed. Low-impact activity — swimming, cycling, controlled pool walking — tends to become realistic around four to six months post-operatively in straightforward cases. Structured return to running or lateral load-bearing activity is generally deferred beyond twelve months, and only where imaging confirms adequate graft integration.

Physiotherapy is the active mechanism of recovery here, not a background formality. Proprioception and ankle strength deteriorate markedly during the offloading period, and their systematic restoration through neuromuscular and strengthening progressions is what converts graft survival into functional capacity.

The return-to-sport outcomes summarised in the previous section reflect what a large patient population achieved over a mean six-year follow-up — a long-term population measure, not a personal target. Patients undergoing revision grafting, or those who have had OCA combined with osteotomy correction, should expect a longer and more variable recovery than those with primary, straightforward repairs.

Getting assessed at MSK Doctors

The decision about whether OCA is appropriate for a given talar dome lesion rests on a consultant assessment that integrates imaging, surgical history, and lesion geometry — not on any single size threshold in isolation. That assessment is the practical next step for anyone whose ankle symptoms have not resolved with conservative care, or whose lesion has already reached the boundaries where marrow stimulation is unlikely to hold.

For patients outside London, MSK Doctors clinics in Sleaford (Lincolnshire) and Grantham offer consultant-led review and diagnostic imaging without a GP referral or NHS-style waiting list. Patients with recent ankle scans should bring them; where updated imaging is needed, that can be arranged through the same referral point. Appointments can be booked online at mskdoctors.com. Patients in London can access the same specialist pathway through the London Cartilage Clinic.

What the evidence presented across this article consistently shows is that OCA, used within the right clinical context, offers a meaningful route to sustained joint function in a patient group — young, active, predominantly post-traumatic — for whom the alternatives are either technically insufficient or premature.